James J. Ignatz-Hoover

Hematology

11100 Euclid Ave Fl 1
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Serological pseudoprogression of multiple myeloma after treatment with teclistamab.

Serological pseudoprogression of multiple myeloma after treatment with teclistamab.

Journal: Leukemia & lymphoma

Published: December 16, 2025

Engineering TCR-directed T-cells for the treatment of multiple myeloma.

Engineering TCR-directed T-cells for the treatment of multiple myeloma.

Journal: Frontiers in immunology

Published: November 26, 2025

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity.

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 18, 2024

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.

Journal: Nature communications

Published: January 30, 2024

Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity.

Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity.

Journal: Molecular cancer therapeutics

Published: December 29, 2023

HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity.

HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity.

Journal: Cancer research communications

Published: November 27, 2023

Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases.

Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases.

Journal: Cancers

Published: October 16, 2023

Current and Emerging Strategies to Treat Urothelial Carcinoma.

Current and Emerging Strategies to Treat Urothelial Carcinoma.

Journal: Cancers

Published: July 29, 2023

Vactosertib, a novel TGF-β1 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma.

Vactosertib, a novel TGF-β1 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma.

Journal: Research square

Published: July 28, 2023

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma.

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma.

Journal: Oncology (Williston Park, N.Y.)

Published: April 27, 2023

Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.

Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.

Journal: Frontiers in cellular and infection microbiology

Published: April 21, 2022

Therapeutics to harness the immune microenvironment in multiple myeloma.

Therapeutics to harness the immune microenvironment in multiple myeloma.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: February 23, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026